Erbitux gets final rejection in EU for lung cancer
This article was originally published in Scrip
Merck KGaA's Erbitux (cetuximab) has suffered its final rejection for the treatment of advanced non-small cell lung cancer (NSCLC) in the EU, following a failed appeal over a negative opinion issued by the CHMP for this major indication in July. Merck KGaA said it was "disappointed that NSCLC patients in Europe will not get to benefit from Erbitux".
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.